<?xml version="1.0" encoding="UTF-8"?>
<p id="para0035">The combination of two antiviral molecules (lopinavir, a human immunodeficiency virus type 1 aspartate protease inhibitor, plus ritonavir, an inhibitor of the cytochrome P450 to increase its plasma half-life) has been tried for COVID-19. However, convincing data are lacking as recently demonstrated, the association of lopinavirâ€“ritonavir has proved unfruitful compared with standard of care in an adult cohort of hospitalized patients with severe SARS-CoV-2 pneumonia 
 <xref rid="bib0044" ref-type="bibr">[44]</xref>. Therefore, further antiviral agents have been proposed.
</p>
